Systemic reactive amyloidosis associated with Castleman's disease: Serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum

Journal of Clinical Pathology

Volumn 50, Issue 11, 1997, Pages 965-967

  Ikeda, Shu Ichi ^a   Chisuwa, Hisanao ^a   Kawasaki, Seiji ^a   Ozawa, Junko ^b   Hoshii, Yoshinobu ^c   Yokota, Tadaaki ^d   Aoi, Tuneto ^e  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

^c YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KOKURA MEMORIAL HOSPITAL   (Japan)

^e Department of Medicine   (Japan)

Author keywords

Amyloid; Castleman's disease; Interleukin 6; Serum amyloid A

Indexed keywords

AMYLOID PRECURSOR PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; SERUM AMYLOID A; TUMOR NECROSIS FACTOR;

ACUTE PHASE RESPONSE; ADULT; AMYLOIDOSIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; BLOOD LEVEL; CASE REPORT; FEMALE; HUMAN; HUMAN TISSUE; LYMPHADENECTOMY; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL;

EID: 0030732190     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.50.11.965     Document Type: Article

References (10)

1. Husby G, Marhaug G, Dowton B, Sletten K, Sipe JD. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid: International Journal of Experimental and Clinical Investigation 1994;1:119-37.
2. Banks RE, Forbes MA, Storr M, Higginson J, Thompson D, Raynes J, et al. The acute phase protein response in patients recieving subcutaneous IL-6. Clin Exp Immunol 1995;102: 217-23.
3. Chan WC, Hargreaves H, Keller J. Giant lymph node hyperplasia with unusual clinicopathologic features. Cancer 1984;53:2135-9.
4. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985;3:1202-16.
5. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathologic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74:1360-7.
6. Beck JT, Hsu S-M, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Alleviation of systemic manifestations of Castleman's disease by monocional anti-interleukin-6 antibody. N Engl J Med 1994;330:602-5.
7. Ordi J, Grau JM, Junque A, Nomdedeu B, Antonio P, Antonio C. Secondary (AA) amyloidosis associated with Castleman's disease. Report of two cases and review of the literature. Am J Clin Pathol 1993;100:394-7.
8. Perfetti V, Bellotti V, Maggi A, Arbustini E, De Benedetti F, Paulli M, et al. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. Am J Hematol 1994;46:189-93.
9. Kazes I, Deray G. Jacobs C. Castleman disease and renal amyloidosis. Ann Intern Med 1995;122:395-6.
10. Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988;232:347-50.